Top 3 drug approvals in oncology in July: nivolumab, ipilimumab and talquetamab

This month, the UK has experienced a wealth of new treatment options for various cancer types as the National Institute for Health and Care Excellence (NICE) issued approvals left, right and center. Additionally, the July meeting of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) paved the way for an array of positive backings for several of cancer drugs. Piqray® (alpelisib) + Trodelvy® (sacituzumab govitecan) Approved: 14 July 2022 Approving body: NICE Indication: Advanced breast cancer In mid-July, NICE approved not one, but two new treatment options for advanced breast cancer, maintaining their...